A new type of drug that blocks one of cancer’s key evolutionary escape routes from chemotherapy could be used to treat aggressive breast cancers, a new study has shown.

Combining a new class of drug with two other compounds can significantly shrink lung tumours in mice and human cancer cells, finds a new study led by the Francis Crick Institute and The Institute of Cancer Research, London.

Targeted drugs for breast and lung cancer could be used together to overcome resistance to treatment in several different tumour types, a new study shows.